RUNX2 and cancer: The connective tissue growth factor (CTGF) reduces the ubiquitination-dependent degradation of RUNX2 and promotes RUNX2 acetylation in cancer cells, stabilizing RUNX2 and thereby increasing the production of RANKL and MMPs.